IMMU-18. IMMUNOGENOMIC RESPONDER PHENOTYPE FROM A PHASE I TRIAL OF ANTI-LAG3 OR ANTI-CD137 ALONE AND IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH RECURRENT GBM
Jackson, Christina, Choi, John, Zhang, JiaJia, Piotrowski, Anna, Walbert, Tobias, Desai, Arati, Ahluwalia, Manmeet, Nabors, Burt, Ye, Xiaobu, Desideri, Serena, Fisher, Joy, Wen, Patrick, Grossman, StuVolume:
21
Journal:
Neuro-Oncology
DOI:
10.1093/neuonc/noz175.511
Date:
November, 2019
File:
PDF, 88 KB
2019